Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2-Reference-Cited by-同舟云学术

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2

Author:

Fathi Amir T.¹²,DiNardo Courtney D.³,Kline Irina⁴,Kenvin Laurie⁴,Gupta Ira⁴,Attar Eyal C.⁵,Stein Eytan M.⁶,de Botton Stephane⁷,

Affiliation:

1. Department of Medicine, Division of Hematology and Medical Oncology, Massachusetts General Hospital Cancer Center

2. Massachusetts General Hospital, Harvard Medical School, Boston

3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston

4. Celgene Corporation, Summit, New Jersey

5. Agios Pharmaceuticals, Inc, Cambridge, Massachusetts

6. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

7. Department of Clinical Hematology, Gustave Roussy, Villejuif, France

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference16 articles.

5. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.;Tallman;Blood,2000

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献